Shares Magazine
10.75p+0.00 (+0.00%)04 Aug 2025, 15:40
Jump to:
Crism Therapeutics Corporation Fundamentals
| Company Name | Crism Therapeutics Corporation | Last Updated | 2025-08-04 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 39.962 m | Market Cap | £4.30 m |
| PE Ratio | 0.03 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.02 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.2312 | Cash Equity Ratio | 0.8692 |
| Quick Ratio | 3.8211 | Current Ratio | 4.96 |
| Price To Book Value | 2.9121 | ROCE | 0 |
Crism Therapeutics Corporation Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Crism Therapeutics Corporation Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | £52,000.00 | £68,000.00 | 0 |
| Intangible Assets | £74,000.00 | £46,000.00 | 0 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £126,000.00 | £114,000.00 | £20.82 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £21,000.00 | £12,000.00 | 0 |
| Cash & Equivalents | £1.28 m | £1,000.00 | £2.88 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £1.82 m | £127,000.00 | £23.75 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | £341,000.00 | £424,000.00 | £615,600.95 |
| Creditors after 1 year | 0 | £304,000.00 | £145,430.56 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £341,000.00 | £728,000.00 | £761,031.51 |
| Net assets | £1.48 m | -£601,000.00 | £22.99 m |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | £66.22 m | 0 | £66.76 m |
| Share Premium | £3.36 m | 0 | £3.53 m |
| Profit / Loss | -£593,000.00 | -£202,000.00 | -£2.15 m |
| Other Equity | £1.48 m | -£601,000.00 | £22.99 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £1.48 m | -£601,000.00 | £22.99 m |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.2312 | 1.2312 | 1.2312 |
| Cash / Equity | 0.8692 | 0.8692 | 0.8692 |
| EPS | -£0.03 | -£0.08 | -£0.22 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | -£933,000.00 | -£98,000.00 | 0 |
| Cashflow before financing | -£1.00 m | -£98,000.00 | 0 |
| Increase in Cash | £1.33 m | -£110,000.00 | -£2.53 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | £25,000.00 | £45,000.00 | 0 |
| Cost of sales | £4,000.00 | £32,000.00 | 0 |
| Gross Profit | £21,000.00 | £13,000.00 | 0 |
| Operating Profit | -£582,000.00 | -£170,000.00 | -£2.15 m |
| Pre-Tax profit | -£593,000.00 | -£202,000.00 | -£2.15 m |
Crism Therapeutics Corporation Company Background
| Sector | Healthcare |
|---|---|
| Activities | Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation anddevelopment. |
| Latest Interim Date | 19 Sep 2024 |
| Latest Fiscal Year End Date | 13 Jun 2025 |
Crism Therapeutics Corporation Directors
| Appointed | Name | Position |
|---|---|---|
| 2011-08-09 | Mr. George William O'Neale Eccles | Non-Executive Director |
| 2024-05-29 | Mr. Thomas Edward Bowens | Non-Executive Director |
| 2009-12-31 | Mr. William Philip McLucas | Non-Executive Director |
| 2009-12-31 | Mr. Eric David McAuslan | Non-Executive Director |
| 2021-06-30 | Mr. Brian Charles Savage | Non-Executive Director |
| 2024-05-29 | Mr. Robert William Schafer | Non-Executive Director,Chairman |
| 2024-05-29 | Mr. Robin Jay Young BSc | Executive Director,Chief Executive Officer |
| 2011-10-03 | Mr. David Fain Wood BA,MBA | Chief Financial Officer & Co Secretary |
| 2011-08-09 | Mr. David Straker-Smith | Non-Executive Director |
| 2024-05-29 | Mr. Paul Terence Gazzard | Non-Executive Director |
| 2020-05-20 | Mr. Ljupco Lou Naumovski | Non-Executive Director |
| 2021-06-30 | Mr. Adam Habib | Executive Director,President |
| 2025-07-03 | Mr. Gerald Douglas Beaney | Non-Executive Director |
| 2025-07-03 | Mr. Andrew James Webb | Executive Director,Chief Executive Officer |
| 2025-06-13 | Dr. Christopher McConville | Executive Director,Chief Scientific Officer |
Crism Therapeutics Corporation Contact Details
| Company Name | Crism Therapeutics Corp |
|---|---|
| Address | Kingston Chambers, P.O. Box 173, Tortola, Road Town |
| Telephone | |
| Website | https://www.crismtherapeutics.com |
Crism Therapeutics Corporation Advisors
| Solicitor | Norton Rose Fulbright (Central Europe) LLP |
|---|---|
| Phone | +7 4999245101 |
| Nominated Adviser | SP Angel |
|---|---|
| Phone | +44 2034700470 |
| Fax | +44 2076291341 |
| Financial Adviser | SP Angel |
|---|---|
| Phone | +44 2034700470 |
| Fax | +44 2076291341 |
| Stockbroker | SP Angel |
|---|---|
| Phone | +44 2034700470 |
| Fax | +44 2076291341 |
| Financial PR Adviser | Yellow Jersey PR Ltd |
|---|
| Solicitor | Fieldfisher |
|---|---|
| Phone | +44 2078614000 |
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8704027573 |
| Nominated Adviser | RBC Capital Markets |
|---|---|
| Phone | 020 7653 4000 |
| Fax | 020 7029 7900 |
| Auditor | BDO LLP |
|---|---|
| Phone | +44 2074865888 |
| Fax | +44 2074873686 |
| Stockbroker | RBC Capital Markets |
|---|---|
| Phone | (020) 7653 4000 |
| Fax | (020) 7029 7900 |
| Financial PR Adviser | Tavistock Communications Ltd |
|---|---|
| Phone | +44 2079203150 |
| Fax | +44 2079203151 |
| Solicitor | Maples and Calder |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Close Brothers Group PLC | 491.40 | 23.53 |
| Lloyds Banking Group PLC | 82.56 | 9.00 |
| Aston Martin Lagonda Global Holdings PLC | 71.60 | 6.79 |
| Watches Of Switzerland Group PLC | 346.20 | 5.94 |
| Ocado Group PLC | 349.10 | 5.56 |
| 4Imprint Group PLC | 3,735.00 | 5.21 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Auction Technology Group PLC | 376.00 | -21.67 |
| Senior PLC | 187.20 | -3.51 |
| Haleon PLC | 355.80 | -2.63 |
| Inchcape PLC | 672.00 | -2.04 |
| Rentokil Initial PLC | 354.30 | -2.02 |
| Pantheon Infrastructure PLC | 102.00 | -1.92 |